Moncton, New Brunswick

Diabetes Treatment and Navigating the World of Reimbursement in Making Therapeutic Choices:

“Rob Has Something to Say, Pay Attention – You Can’t Afford Not to Listen

Allied Health Practitioners

NovoNordisk

Abbott Diabetes Canada

•              TEACH A PERSON TO FISH rather than GIVE THEM THE FISH

•  Navigate criteria for complex coverage within NB

•              TOOLS TO GO FISHING

•  Appraise NB coverage related to diabetes medication, technologies and supplies

•              THERE COULD BE BETTER SPOTS TO FISH , BUT OURS ISN’T TOO BAD

Saint John, New Brunswick

Why is Diabetes Therapy changing?   

 Cardiovascular Outcome Trials  (CVOT)
Cardiorenal Results
SGLT-2 vs. GLP-1

·   Review of the CardioRenal Trial results and potential impact on guidelines and Diabetes Treatment

·   Debate which is better SGLT-2 or GLP-1

·   Review benefits and challenges of each of the classes of SGLT-2 & GLP-1  Medications

Saint John, New Brunswick

The LIBRE System: Overview & Reports &

Boehringer-Ingelheim

·         Demonstrate and provide “Hands On” experience with components of the LIBRE system

·         Troubleshoot potential problems in using the system

·         Review of the available Libre Reports and How to Use them

Fredericton, New Brunswick

Effective Conversations in Diabetes:

Empowering Patients to Optimize Treatment for Cardiac Protection

•   Reframe conversations with patients about these medications to focus first and foremost on the cardiovascular risk-reduction benefits

•   Employ strategies to proactively help themselves and their patients conquer barriers (psychological, medical, social and practical) to starting and maintaining these treatments

Nova Scotia

Updates on the Latest Research and Published Papers

Pharmacists,

Allied HealthCare Workers

·         Open discussions with one of the co-authors

·         Discussions on updates to FIT (Forum for Injection Technique)Canada

Moncton, New Brunswick

KEEP IT SIMPLE: Laying a solid foundation for long-term success with long-acting insulins

Allied HealthCare Practitioners

•   Apply key takeaways from the 2018 Diabetes Canada Clinical Practice Guidelines (CPGs) to clinical practice to successfully start basal insulin, promote patient self-titration, and conduct effective follow-up

•   Discuss individualization of treatment through analysis of patient and insulin characteristics, with a focus on newer long-acting analogues, as per the 2018 Diabetes Canada CPGs

Diagnosis & Treatment of Onychomycosis

•    Urgency to treat

Not just a cosmetic issue

•    Treatment options

Oral therapies

Topical therapies

Canadian clinical pathway

Prevention of recurrence

Fredericton NB

How to Discuss Libre Results: When You do Not have LibreView Reports

Nurse, Nurse Practitioners Allied Health Practitioners,

Physicians

·         Review the different reports available

·         Discuss the various options on which reports and which order to use

·         Review using the reader/phone to review reports in real time

Moncton,NewBrunswick

PILLARS: Primary Care Pillars-

Optimizing the Management of Diabetic Kidney Disease

Pharmacists

• Recognize unmet needs in the management of DKD

• Discuss current standards of care in the treatment of DKD and the need for new therapeutic interventions

Consider the relevance of recent trials and guideline recommendations to your practice

Moncton, New Brunswick

Diagnosis & Treatment of Onychomycosis

Family Physicians

•    Urgency to treat

Not just a cosmetic issue

•    Treatment options

Oral therapies

Topical therapies

Canadian clinical pathway

Prevention of recurrence

Insulin Injection Therapy

Optimization Program (I2-TOP)

Pharmacists

·         Review components of FIT(Forum for Injection Technique) Canada

·         Identify gaps in proper injection technique and injection site rotation

·         Discussions around Novel products to help meet recommendations for proper injection site rotation including Coloured Needle tips

New Brunswick

PILLARS: Primary Care Pillars-

Optimizing the Management of Diabetic Kidney Disease

• Recognize unmet needs in the management of DKD

• Discuss current standards of care in the treatment of DKD and the need for new therapeutic interventions

Consider the relevance of recent trials and guideline recommendations to your practice

New Brunswick

CardioVascular Outcomes Trials (CVOT):

Populations in the Recent Diabetes Outcome Trials:

CARMELINA, CANVAS, DEVOTE, HARMONY, DECLARE, REWIND and CREDENCE

Speciaists

· Relate the populations to the trial outcomes is it a factor or impact

· Discuss the results and outcomes and the populations included

·  Discuss comparisons between the trials and populations studied.

Moncton, New Brunswick

PILLARS: Primary Care Pillars-

Optimizing the Management of Diabetic Kidney Disease

• Recognize unmet needs in the management of DKD

• Discuss current standards of care in the treatment of DKD and the need for new therapeutic interventions

• Consider the relevance of recent trials and guideline recommendations to your practice

Diagnosis & Treatment of Onychomycosis

•    Urgency to treat

Not just a cosmetic issue

•    Treatment options

Oral therapies

Topical therapies

Canadian clinical pathway

Prevention of recurrence

New Brunswick

    The Next Step: Intensifying insulin therapy in patients with type 2 diabetes

•    Recognize when and how to intensify glycemic control with mealtime insulin

•    Identify glycemic variability and how to effectively manage it

•    Compare new insulins available in Canada

Petitcodiac, New Brunswick

In Control: Long-acting insulins for the management of type 2 diabetes

•  Apply strategies to overcome common challenges associated with insulin initiation and optimization and employ knowledge of key concepts, including glucose variability, hypoglycemia and continuous glucose monitoring

•  Compare agent-specific characteristics of the available basal insulins, with a focus on newer basal insulins

FIT (Forum for Injection Technique) Videos

•    Utilizing white board techniques to clarify those principles.

Miramichi ,New Brunswick

KEY:  Keep Educating Yourself

Evidence and Diabetes Guidelines for Primary Care Physicians

•   Review the results of recent clinical studies with SGLT2 inhibitors

•   Use case-based scenarios to help apply and synthesize learnings

Casting New Light on Basal Insulins:

Overcoming Challenges in Diabetes Management with Next Generation Basal Insulins

•   Discuss recent clinical trial results surrounding the action profiles of longer-acting basal insulins

•   Recognize the differences between the available longer-acting basal insulin therapies as demonstrated by recent head-to-head clinical trial results and real-world evidence

KEY:  Keep Educating Yourself

Evidence and Diabetes Guidelines for Primary Care Physicians

•   Review the results of recent clinical studies with SGLT2 inhibitors

•   Use case-based scenarios to help apply and synthesize learnings

Halifax, Nova Scotia

The Winning Edge

•  Review FIT Technique Plus tools for daily practice

•  Also provided Q & A session around injection technique

3 Minute Intervention for Injection Technique

Lesson

•   Develop and Provide “Real Life 3-Minute Intervention” demonstration

•   Also provide Q & A session around injection technique.

Translating the New Evidence in the Management of Type 2 Diabetes

•   Examine new evidence impacting antihyperglycemic selection since the November 2016 Interim Update to the Diabetes Canada Clinical Practice Guidelines

•   Review the selection of antihyperglycemic medication for a patient without CVD who is not reaching glycemic targets with metformin monotherapy

•   Discuss the significance of CVD primary prevention results with antihyperglycemics

Introduction

•     Glycemic management in Canada

•     CDA Guidelines

DPP-4i or SGLT2i?

•     Use of baseline A1C

•     Monotherapy

•     Dual Therapy (Add-on to Metformin)

•     Triple therapy (Add-on to Metformin + SU)

•     Use of baseline eGFR

•     Use in the elderly

Triple therapy

•     SGLT2i add-on to metformin + DPP-4i

•     DPP-4i add-on to metformin + SGLT2i

•     DPP-4i + SGLT2i dual add-on therapy to metformin

MetaboliceffectsofDPP-4iandSGLT2i:
Focus on glucagon and endogenous glucose production

Charlottetown, P.E.I

Basal Insulins:
What’s New, What’s Changed, What’s Stayed the Same

(What the Pharmacist Needs to Know)

•    Review 2 new glargine basal insulin options:

•     Insulin glargine 300 U/mL (Toujeo™)

•    Subsequent entry biologic (SEB) of insulin glargine 100 U/mL       (Basaglar™)

•    Review insulin degludec TRESIBA

•    Review the Toujeo™SoloStar® injection device to ensure safety

•    Discuss how to initiate, transfer and monitor patients on Toujeo^TM

Be The Expert: SGLT-2 Inhibition and Cardiorenal Outcomes

· Discuss the mechanism of action of SGLT2 inhibitors and their efficacy and safety data from Phase 3 trials

· Explain the cardiorenal results from outcome trials with SGLT2 inhibitors and integrate into clinical practice

Differentiate results from large randomized trials and real-world studies

BASAL INSULIN: The truth about newer basal insulin options

• Evaluate the pharmacokinetics, safety and efficacy of new basal insulins, and identify differentiating benefits

• Discuss mechanisms to simplify basal insulin initiation and optimization

Be The Expert: SGLT-2 Inhibition and Cardiorenal Outcomes

· Discuss the mechanism of action of SGLT2 inhibitors and their efficacy and safety data from Phase 3 trials

· Explain the cardiorenal results from outcome trials with SGLT2 inhibitors and integrate into clinical practice

· Differentiate results from large randomized trials and real-world studies

Rexton, New Brunswick

Be The Expert: SGLT-2 Inhibition and Cardiorenal Outcomes

· Discuss the mechanism of action of SGLT2 inhibitors and their efficacy and safety data from Phase 3 trials

· Explain the cardiorenal results from outcome trials with SGLT2 inhibitors and integrate into clinical practice

· Differentiate results from large randomized trials and real world studies

Be The Expert: SGLT-2 Inhibition and Cardiorenal Outcomes

· Discuss the mechanism of action of SGLT2 inhibitors and their efficacy and safety data from Phase 3 trials

· Explain the cardiorenal results from outcome trials with SGLT2 inhibitors and integrate into clinical practice

· Differentiate results from large randomized trials and real world studies

CVOTs and GLP-1RAs

•Reflect on specific patient and agent characteristics and how to optimize T2D management using the evolving GLP-1RA class•

•Discuss how to integrate GLP-1RAs into practice, based on the Diabetes Canada guidelines

CVOTs and GLP-1RAs

Allied Health Practitioners

•Reflect on specific patient and agent characteristics and how to optimize T2D management using the evolving GLP-1RA class•

•Discuss how to integrate GLP-1RAs into practice, based on the Diabetes Canada guidelines

CVOTs and GLP-1RAs

Allied Health Practitioners

•Reflect on specific patient and agent characteristics and how to optimize T2D management using the evolving GLP-1RA class•

•Discuss how to integrate GLP-1RAs into practice, based on the Diabetes Canada guidelines

Engaging Patients and Growing Your Pharmacy Business

Engaging Patients and Growing Your Pharmacy Business

“Real World Evidence im Basal Insulin Therapy”

Pharmacists

•To evaluate real-word hypoglycemia risk and clinical outcomes in patients with T2D who had been receiving treatment with basal insulin and transferred to Gla-300

•To compare changes in clinical measures before and after initiation and dosage of Gla-100 and Gla-300 in insulin-naïve patients with T2D in a real-world setting

•To evaluate clinical outcomes of patients with T2D using basal insulin who were transferred to either Gla-300 or other basal insulins in real-world clinical practice

Engaging Patients and Growing Your Pharmacy Business

1,2,3 Go!

•Understand the Vascular Protection Check list and how to manage patients with and without established cardiovascular disease

•Discuss “matching the agent to the patient” based on the November 2016 CDA-CPG Update with a focus on exploring strategies that avoid or minimize the risk of adverse events  in patients with T2DM (hypoglycemia, SADMANS…)

1,23, Go!

•Understand the Vascular Protection Check list and how to manage patients with and without established cardiovascular disease

•Discuss “matching the agent to the patient” based on the November 2016 CDA-CPG Update with a focus on exploring strategies that avoid or minimize the risk of adverse events  in patients with T2DM (hypoglycemia, SADMANS…)

Evolution of mealtime control: Advancements towards a physiologic profile

•Describe the pathophysiology of postprandial hyperglycemia in diabetes.

•Explore the rationale and applicability of rapid-acting insulin analogues in type 1 and type 2 diabetes

•Understand the Vascular Protection Check list and how to manage patients with and without established cardiovascular disease

•Discuss “matching the agent to the patient” based on the November 2016 CDA-CPG Update with a focus on exploring strategies that avoid or minimize the risk of adverse events  in patients with T2DM (hypoglycemia, SADMANS…)

•Understand the Vascular Protection Check list and how to manage patients with and without established cardiovascular disease

•Discuss “matching the agent to the patient” based on the November 2016 CDA-CPG Update with a focus on exploring strategies that avoid or minimize the risk of adverse events  in patients with T2DM (hypoglycemia, SADMANS…)

·         Review of the CDA CPG 2016 pharmacological management 2016 update

·         Discuss the various coverage options for patients from different backgrounds and insurance coverages

·         Discuss the various treatment barriers and potential approaches to facilitate quick and efficient methods in obtaining approvals

CVOT’s: Getting to the Heart of the Matter

Subsequent Entry Biologics (SEB): A New option in Insulin Therapy

·         Explain the differences between subsequent entry biologic (SEB)
and reference products;

·         Describe the safety and efficacy of SEB insulin

·         Identify the clinical implications surrounding the arrival of SEB insulin

Diabetes Gadgets & Gizmos: Helping patients select, start, and succeed with diabetes devices

•       Recognize the role that diabetes devices play in enhancing patient self-management

•       Compare and contrast available diabetes devices and explain key features and benefits

•       Select the most suitable devices to individualize diabetes care based on patient characteristics and management goals

The Pharmacist’s Role in the
Management of Type 2 Diabetes — Integrating SGLT2 Inhibitors

• Description Describe publically funded pharmacy services available for patients with diabetes
• Understand when and why pharmacists should intervene for patients with diabetes
• Explain the pathogenesis of diabetes and where current medications fit in the treatment of patients with T2DM
• Review the role of SGLT2 inhibitors in the treatment of T2DM, including efficacy, side effects and safety
• Discuss how individualization of therapy can be used to choose when a SGLT2 can be recommended for a patient with T2DM

·         Appraise and interpret data emerging from large T2DM CV safety trials

·         Personalize glucose-lowering therapy according to patient characteristics and CV risk profile

Basal Insulins:
What’s New, What’s Changed, What’s Stayed the Same : (What the Pharmacist Needs to Know)

•       Review 2 new glargine basal insulin options:

–      Insulin glargine 300 U/mL (Toujeo™)

–      Subsequent entry biologic (SEB) of insulin glargine 100 U/mL       (Basaglar™)

•       Review the Toujeo™ SoloStar^® injection device to ensure safety

•       Discuss how to initiate, transfer and monitor patients on Toujeo^TM

·         Ask the relevant questions to guide the individualization of treatment options and take into consideration patient and medication factors

·         Distinguish the role of newer pharmacological agents as add-on therapies to metformin

Injectable Therapies: Oh the challenges!! ,

Too Many Choices –How do we choose?

Just whose job is it anyway?

·         Identify the differences between the products and discuss how they may be positioned.

·         Discussion on the new agents available: coverage, how do we choose, where does it fit

·         Discussion on the who has the best role in educating the patient on their options.

·         Discussion on who is best suited to do the injectable training.

·         Review a patient for factors that increase the risk of onychomycosis infection

·         Counsel a patient on the goals of treatment and expectations of pharmacotherapy

·         Determine the role for systemic or topical therapy in the management of onychomycosis

·         Educate a patient on strategies to reduce their risk of onychomycosis or a recurrence of the infection

·         The role of compliance and improving outcomes: are the Extended Release products a better choice in some patients?

·         The evolving role of Lodalis (Colesevelam) in managing the diabetes patient who also is not at goal with their lipid targets

·         The Increased incidence of Onychomycosis in Diabetes, the increased risk of complications due to Onychomycosis, and what are the treatment options available , and how to use them.

Finding the Key to Individualizing Treatment in Type 2 Diabetes

Practical Nurses

·         Ask the relevant questions to guide the individualization of treatment options and take into consideration patient and medication factors

·         Distinguish the role of newer pharmacological agents as add-on therapies to metformin

Fredericton, New Brunswick

New CDA Clinical Practice Guideline Interim Update and Finding the Key to Individualizing Treatment in Type 2 Diabetes

·         Identify appropriate therapeutic targets for individuals with Type 2 Diabetes, particularly those with comorbidities or complications

·         Ask the relevant questions to guide the individualization of treatment options and take into consideration patient and medication factors

·         Distinguish the role of newer pharmacological agents as add-on therapies to metformin

Pharmacy Practice Pilot Presentation

Pharmacy Students

•       Review 2 new glargine basal insulin options:

•       Insulin glargine 300 U/mL (Toujeo™) and

Biosimilar of insulin glargine 100 U/mL (Basaglar™)

•       Review the injection device to ensure safety

•       Discuss how to initiate, transfer and monitor patients on Toujeo^TM

“I am Embarrassed to Take my Shoes Off” : Managing your Patients with Onychomycosis

·           Review a patient for factors that increase the risk of onychomycosis infection

·           Counsel a patient on the goals of treatment and expectations of pharmacotherapy

·           Determine the role for systemic or topical therapy in the management of onychomycosis

·           Educate a patient on strategies to reduce their risk of onychomycosis or a recurrence of the infection

Finding the Key to Individualizing Treatment in Type 2 Diabetes

·         Ask the relevant questions to guide the individualization of treatment options and take into consideration patient and medication factors

·         Distinguish the role of newer pharmacological agents as add-on therapies to metformin

INSIDE INSULIN PUMPS: A comparison of rapid-acting insulin analogues

•          STABILITY OF RAIA IN CSII:IN VITRO STUDIES

•          Clinical trials comparing RAIA in CSII

•          CSII is based on a continuous infusion of insulin via an external pump, addressing both basal and prandial requirements¹

•          CSII allows administration of insulin that closely mimics physiological secretion of insulin²

•          Properties of a ideal rapid-acting insulin analogue for optimal use in CSII include³:

•       Rapid-action

•       Soluble

•       Uniform absorption characteristic

New Advances in Insulin Therapy

•       Describe the current challenges with insulin use and desired properties of new insulins;

•       Define what a biosimilar is and introduce the clinical profile of biosimilar glargine (LY2963016);

•       Review key clinical outcomes from long-acting basal insulins recently approved and in development;

•       Explain the rationale and benefits of the fixed combination of basal insulin and GLP-1 receptor agonist therapy in the management of T2D; and

•       Describe key clinical trial outcomes from two upcoming bolus insulin therapies.

·         Ask the relevant questions to guide the individualization of treatment options and take into consideration patient and medication factors

·         Distinguish the role of newer pharmacological agents as add-on therapies to metformin

Finding the Key to Individualizing Treatment in Type 2 Diabetes

·         Ask the relevant questions to guide the individualization of treatment options and take into consideration patient and medication factors

·         Distinguish the role of newer pharmacological agents as add-on therapies to metformin

Diabetes Gadgets & Gizmos: Helping patients select, start, and succeed with diabetes devices

•       Recognize the role that diabetes devices play in enhancing patient self-management

•       Compare and contrast available diabetes devices and explain key features and benefits

•       Select the most suitable devices to individualize diabetes care based on patient characteristics and management goals

How to Initiate the Insulin Conversation With Your Patients

• Discuss the most common types of insulin regimens and their mode of action
• Explain the complications associated with hypoglycemia and the risk of cardiovascular (CV) events
• Implement an action plan for insulin patients by utilizing  expanded scope of practice

O.P.T.I.O.N.S
Offering Pharmacists Therapeutic Interventions & Optimizing Next Steps

·         Discussion on how they started, how they are evolving, possible future steps.

·         Presented a typical process of a clinic

·         Answered Questions as par of a panel once project was presented

The Role of the Kidneys in Diabetes Control: Focus on SGLT2 Inhibitors-Concept and Questions

•       Describe the SGLT2 inhibitors  (sodium/glucose cotransporter 2), their mode of action and pharmacodynamic effects;

•       Discuss the potential role of SGLT2 inhibitors in the treatment of type 2 diabetes.

Medtronic Diabetes Updates

·         Insulin Pumps

·         New Blood Glucose Meters

·         New Therapies available

·         General discussions within the group of 50 + participants

Glumetza – where does it fit in diabetes management?

Lodalis – where does it fit in the diabetic hypercholesterolemia comorbidity patient?

• Description Why LDL-C Matters
• Reaching Therapeutic Goals: Challenges
• Statin Therapy in a Nutshell
• Open Forum on Add-on Therapy options
• Lodalis Mode of Action
• Lodalis Efficacy Data
• Lodalis Primary Features
• Lodalis vs. other Add-On Therapies
• Lodalis reimbursement across Canada
• Open Forum on Lodalis Clinical Use

“Hands On” Diabetes

•          Assess for and manage lipohypertrophy

•          Perform a proper foot exam, including the use of a monofilament to detect neuropathy

“ Unique Therapeutic Agents for Diabetes and Your “Cholestabetes” Patient”

·         Discussion of novel therapeutic approaches to management of Diabetes especially when Metformin is resulting in tolerance issues. Role of Extended Release Metformin

·         How these therapeutic agents work, where might they fit in the continuum of treatment, where should they not be used, proper dosing and usage information

“ Hands on Diabetes”

·         Assess for and manage Lipohypertrophy

·         Perform a proper foot exam, including the use of a monofilament to detect and screen for neuropathy.

FIT Forum for Injection Technique Canada: Recommendation for Best Practice In Inj- 2^nd EDITION Updates and What’s new /Changed.

Motivational Interviewing: Getting to the point

NovoNordisk Canada

• Identify the role for both insulin and non-insulin injectable therapies in diabetes management according to Canadian Diabetes Association (CDA) 2013 Clinical Practice Guidelines

·         Recognize challenges faced by healthcare providers (HCPs) in the recommendation and initiation of injectable therapies in diabetes management

• Utilize motivational interviewing techniques to identify and overcome common patient challenges related to insulin and non-insulin injectable therapies

Evolution of a Retail Pharmacy Practice

·         How I started , what went wrong- what really worked, role of mentorships, what next steps I see for the graduates, discussions around their point of view .

·         Facilitated the delivery of discussions around the expanded role of pharmacists, tools that work, experience around the communication with other healthcare professionals, taking it to the next level.

·         Explain the SGLT2 inhibitors, their pharmacodynamics effects and their role in Type 2 diabetes;

·         Discuss the indications and appropriate clinical applications of canagliflozin, the first in the SGLT2 inhibitor class for Type 2 diabetes management.

Feel IT, Try IT, Switch IT”

Exploring Lipohypertrophy

& Benefits of proper Injection Technique

UPDATED VERSION

Feel IT

•       Understand what lipohypertrophy is, how it develops and how to prevent it.

•       Learn how you can assess and identify lipohypertrophy (lipos) in your practice.

•       Review practical tips for treatment of lipohypertrophy.

Try IT

•       Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

•       Understand the impact of needle length in relation to lipohypertrophy.

•       Recognize the rationale for timely initiation and intensification of treatment to achieve glycemic targets

•       Understand how currently available treatment options compare with respect to key challenges in diabetes management: A1C, weight and hypoglycemia

•       Implement effective strategies to help patients and health practitioners overcome barriers to treatment at various stages of the treatment continuum

•       Recognize importance of establishing individualized targets (i.e., A1C, weight) based on patient characteristics

Feel IT, Try IT, Switch IT”

Exploring Lipohypertrophy

& Benefits of proper Injection Technique

UPDATED VERSION

Feel IT

•       Understand what lipohypertrophy is, how it develops and how to prevent it.

•       Learn how you can assess and identify lipohypertrophy (lipos) in your practice.

•       Review practical tips for treatment of lipohypertrophy.

Try IT

•       Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

•       Understand the impact of needle length in relation to lipohypertrophy.

“ So Why is This Not Happening”

•       Understand the concept of clinician inertia regarding starting insulin for Type 2 Diabetes.

•       Understanding the benefits of early insulinization for Type 2 Diabetes and become familiar with strategies to overcome barriers to initiating discussions of insulin with those with Type 2 Diabetes.

•       Understand the concept of psychological insulin resistance (PIR) in patients with Type 2 diabetes and become familiar with how to assess PIR in those living with Type 2 Diabetes.

·         Become familiar with change interventions using motivational interviewing, cognitive restructuring and fear management

Feel It, etc,

Nurse Practitioner/

Dietitian

Pharmacist CME

(Multidisciplinary Healthcare Provider Presentation

Feel IT

•       Understand what lipohypertrophy is, how it develops and how to prevent it.

•       Learn how you can assess and identify lipohypertrophy (lipos) in your practice.

•       Review practical tips for treatment of lipohypertrophy.

Try IT

•       Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

•       Understand the impact of needle length in relation to lipohypertrophy.

SGLT-2  The New Kid on the Block

Nurse Practitioner/

Dietitian

Pharmacist CME

(Multidisciplinary Healthcare Provider Presentation

·         Explain the SGLT2 inhibitors, their pharmacodynamic effects and their role in Type 2 diabetes;

·         Discuss the indications and appropriate clinical applications of canagliflozin, the first in the SGLT2 inhibitor class for Type 2 diabetes management.

Insulin Academy

Nurse Practitioner/

Dietitian

Pharmacist CME

(Multidisciplinary Healthcare Provider Presentation

•       Identify when T2DM patients need to start insulin therapy

•       Implement simple strategies for starting insulin

•       Identify T2DM patients currently on basal insulin therapy that need mealtime insulin

•       Implement simple strategies to add and adjust mealtime insulin

“ So Why is This Not Happening”

•       Understand the concept of clinician inertia regarding starting insulin for Type 2 Diabetes.

•       Understanding the benefits of early insulinization for Type 2 Diabetes and become familiar with strategies to overcome barriers to initiating discussions of insulin with those with Type 2 Diabetes.

•       Understand the concept of psychological insulin resistance (PIR) in patients with Type 2 diabetes and become familiar with how to assess PIR in those living with Type 2 Diabetes.

·         Become familiar with change interventions using motivational interviewing, cognitive restructuring and fear management

Exploring Lipohypertrophy

& Benefits of proper Injection Technique

UPDATED VERSION

Bayer Healthcare

Feel IT

•       Understand what lipohypertrophy is, how it develops and how to prevent it.

•       Learn how you can assess and identify lipohypertrophy (lipos) in your practice.

•       Review practical tips for treatment of lipohypertrophy.

Try IT

•       Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

•       Understand the impact of needle length in relation to lipohypertrophy.

•       Recognize the rationale for timely initiation and intensification of treatment to achieve glycemic targets

•       Understand how currently available treatment options compare with respect to key challenges in diabetes management: A1C, weight and hypoglycemia

•       Implement effective strategies to help patients and health practitioners overcome barriers to treatment at various stages of the treatment continuum

•       Recognize importance of establishing individualized targets (i.e., A1C, weight) based on patient characteristics

Exploring Lipohypertrophy

& Benefits of proper Injection Technique

UPDATED VERSION

(MTPA)

Feel IT

•       Understand what lipohypertrophy is, how it develops and how to prevent it.

•       Learn how you can assess and identify lipohypertrophy (lipos) in your practice.

•       Review practical tips for treatment of lipohypertrophy.

Try IT

•       Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

•       Understand the impact of needle length in relation to lipohypertrophy.

Answering your most frequently asked questions

•       Understand the two classes of incretin agents and their mode of action

•        Differentiate between GLP-1 receptor agonists and DPP-4 inhibitors

•       Review the efficacy and safety data of currently available incretin agents and where they fit in the 2013 CDA guidelines

•       Explain how to optimally incorporate incretin therapies into clinical practice and to discuss the rationale for a personalized evidence-based approach to care

(Vascular 2013)

Description: Upon completion of this continuing professional development program, participants will be better able to:

•       List the signs, symptoms, and risk factors for developing DPN

•       Screen for DPN as part of routine management of diabetes and its co-morbidities

•       Apply tools to counsel the patient on evidence-based treatment options for painful DPN, and follow up with appropriate interventions

•       Discuss the basic concepts of good foot care to prevent and screen for diabetes foot complications

Answering your most frequently asked questions

Nurse Practitioner/

Dietitian

Pharmacist CME

(Multidisciplinary Healthcare Provider Presentation)

•       Understand the two classes of incretin agents and their mode of action

•        Differentiate between GLP-1 receptor agonists and DPP-4 inhibitors

•       Review the efficacy and safety data of currently available incretin agents and where they fit in the 2013 CDA guidelines

•       Explain how to optimally incorporate incretin therapies into clinical practice and to discuss the rationale for a personalized evidence-based approach to care

•       Familiar with most major changes within the 2013 CDA clinical practice guidelines

•       Able to apply the recommendations in clinical practice and be familiar with online resources.

Diabetic Peripheral Neuropathy: The Diabetic Foot A Pharmacists Role

Description Upon completion of this continuing professional development program, participants will be better able to:

•       List the signs, symptoms, and risk factors for developing DPN

•       Screen for DPN as part of routine management of diabetes and its co-morbidities

•       Apply tools to counsel the patient on evidence-based treatment options for painful DPN, and follow up with appropriate interventions

•       Discuss the basic concepts of good foot care to prevent and screen for diabetes foot complications

•       Understand what lipohypertrophy is, how it develops and how to prevent it

•       Learn how you can assess and identify lipohypertrophy (lipos)

•       Review practical tips for treatment of lipohypertrophy

•       Review proper injection technique (IT) for people living with diabetes, including proper site rotation

•        Understand the impact of needle length in relation to lipohypertrophy

Innovations in Anaphylaxis: Diagnosis, Treatment, and Management of Anaphylaxis

1. 1. Describe the causes, signs, and symptoms of anaphylaxis.
   2. Identify gaps in the diagnosis and management of anaphylaxis.
   3. Understand the diagnostic tests for food allergy.
   4. Identify the appropriate treatment of acute anaphylaxis and long-term management for patients at risk.

The treatment options are provided with “hands-on” practice including the newer devices and comparisons between each are provided discussing both potential advantages of each device style as well as potential concerns as discussed during presentation.

Monitoring with Purpose: Blood Glucose Pattern Management

Incretins: Addressing the Multifactorial Nature of Type 2 Diabetes

Healthcare Professional CME

Incretins: Addressing the Multifactorial Nature of Type 2 Diabetes

Challenging the Hypoglycemia Care Gap 

The objectives of Challenging the Hypoglycemia Care Gap are:

• Examine the prevalence of hypoglycemia in type 2 diabetes patients on insulin
• Describe adverse outcomes associated with hypoglycemia
• Assess for hypoglycemia using simple practice tools
• Identify several strategies to minimize and manage hypoglycemia in type 2 patients using insulin

Challenging the Hypoglycemia Care Gap 

The objectives of Challenging the Hypoglycemia Care Gap are:

• Examine the prevalence of hypoglycemia in type 2 diabetes patients on insulin
• Describe adverse outcomes associated with hypoglycemia
• Assess for hypoglycemia using simple practice tools
• Identify several strategies to minimize and manage hypoglycemia in type 2 patients using insulin

“Feel IT, Try IT, Switch IT”

This presentation will present these 3 main topics:

Feel IT

• Understand what lipohypertrophy is, how it develops and how to prevent it.
• Learn how you can assess and identify lipohypertrophy (lipos) in your practice.
• Review practical tips for treatment of lipohypertrophy.

Try IT

• Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

• Understand the impact of needle length in relation to lipohypertrophy.

The concepts will be presented using a typical insulin case presentation in a patient who has been using insulin for about 10 years. The patient has had increasing doses of insulin over the years but also has more variability of glycemic control. By investigating the impact of lipohypertrophy and then applying the FIT (Forum for Injection Technique) recommendations, the program will illustrate how as pharmacists we may help overcome the challenges of “lipo’s” by identifying poor injection technique as part of a therapy review.  The role of proper needle length in avoiding intramuscular injections and its potential for causing inconsistent insulin absorption is also discussed.

Challenging the Hypoglycemia Care Gap 

The objectives of Challenging the Hypoglycemia Care Gap are:

• Examine the prevalence of hypoglycemia in type 2 diabetes patients on insulin
• Describe adverse outcomes associated with hypoglycemia
• Assess for hypoglycemia using simple practice tools
• Identify several strategies to minimize and manage hypoglycemia in type 2 patients using insulin

This presentation will present these 3 main topics:

Feel IT

• Understand what lipohypertrophy is, how it develops and how to prevent it.
• Learn how you can assess and identify lipohypertrophy (lipos) in your practice.
• Review practical tips for treatment of lipohypertrophy.

Try IT

• Review proper injection technique (IT) for people living with diabetes, including proper site rotation.

Switch IT

• Understand the impact of needle length in relation to lipohypertrophy.

The concepts will be presented using a typical insulin case presentation in a patient who has been using insulin for about 10 years. The patient has had increasing doses of insulin over the years but also has more variability of glycemic control. By investigating the impact of lipohypertrophy and then applying the FIT (Forum for Injection Technique) recommendations, the program will illustrate how as pharmacists we may help overcome the challenges of “lipo’s” by identifying poor injection technique as part of a therapy review.  The role of proper needle length in avoiding intramuscular injections and its potential for causing inconsistent insulin absorption is also discussed.

Incretins: Addressing the Multifactorial Nature of Type 2 Diabetes

New Brunswick

Diabetes in Pharmacy Practice

In addition discussions involving the new emphasis on individualizing therapy, goals, and treatments, by visiting the various criteria in determining these objectives will be presented.

Managing Your Diabetes: The Journey from Metformin to Insulin

New Brunswick, Canada

Simple Steps: Starting and Intensifying Insulin in Type 2 Patients

New Brunswick, Canada

Simple Steps: Starting and Intensifying Insulin in Type 2 patients

British Columbia, Canada

Diabetes Painful NEUROPATHY: A Pharmacy Case

Simple Steps: Starting and Intensifying Insulin in Type 2 patients

Simple Steps: Starting and Intensifying Insulin in Type 2 patients

New Brunswick, Canada

Helping You to Help Your Patients With Type 2 Diabetes

New Brunswick, Canada

Monitoring with Purpose: Blood Glucose Pattern Management

Monitoring with Purpose: Blood Glucose Pattern Management

British Columbia, Canada

Are Your Patients Fit? Release of the Canadian Injection Recommendations

British Columbia, Canada

Diabetes Strategy for Pharmacists

New Brunswick, Canada

Are Your Patients Fit? Release of the Canadian Injection Recommendations

New Brunswick, Canada

Diabetes Painful Neuropathy: A Pharmacy Case

New Brunswick, Canada

Monitoring with Purpose: Blood Glucose Pattern Management

Integrating Incretins into Everyday Management of Diabetes

Diabetes Painful Neuropathy: A Pharmacy Case

New Brunswick, Canada

Are Your Patients Fit? Release of the Canadian Injection Recommendations

Diabetes Painful Neuropathy: A Pharmacy Case

New Brunswick, Canada

Pattern Management

Star System Launch

New Brunswick, Canada

Anaphylaxis and its Treatment: New Program Developed

New Brunswick, Canada

Treat to Target: Insulin Therapies

Star System Launch

Prince Edward Island, Canada

Forum for Injection Techniques (FIT)/ Overview of Incretins

New Brunswick, Canada

Forum for Injection Techniques (FIT)/ Overview of Insulin 201

New Brunswick, Canada

The Pharmacist’s Role in the Management of Type 2 Diabetes:

Integrating GLP-1 Therapy in Diabetes Patient Care Management

Are Your Patients FIT?  Release of the Canadian Injection Recommendations

New Brunswick, Canada

Anaphylaxis and its Treatment with Epi-Pen & Twinject

Diabetes Strategy for Pharmacists

New Brunswick, Canada

Introduction to Incretins Insulin, and Injection Devices

New Brunswick, Canada

FIT Canada (Forum for Injection Technique)

New Brunswick, Canada

Helping You to Help Your Patients With Type 2 Diabetes

Influencing Best Practice in Injection Technique

Nurse CDE NP

New Brunswick, Canada

Incretins: GLP-1 vs. DPP-IV, Focus on Liraglutide

The View on Diabetes

New Brunswick, Canada

Update on Insulin & Insulin Delivery Devices

New Brunswick, Canada

Helping You to Help Your Patients With Type 2 Diabetes

Insulin Pump Therapy: Just the Basics

Diabetes Workshop: The How to of Managing Diabetes…

A Prescription of Pharmacists

Helping You to Help Your Patients With Type 2 Diabetes

New Brunswick, Canada

Circadian Rhythm of Blood Pressure: Implications for Clinical Practice

New Brunswick, Canada

Helping You to Help Your Patients With Type-2 Diabetes

New Brunswick, Canada

A Review of Medications & an Update on New Devices

Multidisciplinary

Health Professions

Diabetes Workshop: The How to of Managing Diabetes…

A Prescription of Pharmacists

Helping You to Help Your Patients With Type 2 Diabetes

The 5 Minute Manager

New Brunswick, Canada

Diabetes Care Update and Insulin Pump Introduction

New Brunswick, Canada

Medication: It’s Not Always About Your Blood Sugars

New Brunswick, Canada

Update on Diabetes Medications & Treatments

New Brunswick, Canada

Medications: Trials & Tribulations

New Brunswick, Canada

Long Acting Insulin Analogues: Focus on Glargine

New Brunswick, Canada

Signature Speaker Series: Diabetes: What You Need to Know

New Brunswick, Canada

Targeting Patient Needs when Treating & Managing Diabetes

CHE/CME

British Columbia, Canada

Establishing a Pharmacist/CDE Practice within a Retail Pharmacy Setting

Prince Edward Island, Canada

Diabetes Education: Where Dies Pharmacy Fit? How We Can Make a Difference!

New Brunswick, Canada

Diabetes Education: Where Dies Pharmacy Fit? How We Can Make a Difference!

New Brunswick, Canada

Diabetes Education: Where Dies Pharmacy Fit? How We Can Make a Difference!

New Brunswick, Canada

Diabetes Education: Where Dies Pharmacy Fit? How We Can Make a Difference!

New Brunswick, Canada

The Art of Diabetes Education & Care

CME/CHE

New Brunswick, Canada

S.M.A.R.T. Therapy: A New Paradigm in Asthma Therapy

Prince Edward Island, Canada

Advances in Pharmaceutical Science & New Horizons in Pharmacotherapy

CHE

New Brunswick, Canada

Ask the Expert

New Brunswick, Canada

Optimizing Diabetes Care

New Brunswick

Ask the Expert

New Brunswick, Canada

Self Monitoring of Blood Glucose

You Don’t Have to be UltraSmart to use the UltraSmart Meter

New Brunswick, Canada

Self Monitoring of Blood Glucose

You Don’t Have to be UltraSmart to use the UltraSmart Meter

New Brunswick, Canada

Self Monitoring of Blood Glucose

You Don’t Have to be UltraSmart to use the UltraSmart Meter

New Brunswick, Canada

Self Monitoring of Blood Glucose

You Don’t Have to be UltraSmart to use the UltraSmart Meter

New Brunswick, Canada

Chronotherapy, Glumetza and it’s Role in Treatment of Diabetes

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen and Twinject

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen and Twinject

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen and TwinJect Device

Insulin Pump Therapy 101: Just the Basics

New Brunswick, Canada

Long Acting Analogues: One Year Later

New Brunswick, Canada

Creating Diabetes Magic

New Brunswick, Canada

What You Need to Know About Diabetes

New Brunswick, Canada

Simplified: Starting Insulin & Managing Patients

New Brunswick, Canada

From Pills to the Gila Monster: How We Treat Your Diabetes

New Brunswick, Canada

Medication & Diabetes: Establishing The Foundation

New Brunswick, Canada

Diabetes Survival: Things You Need To Know

New Brunswick, Canada

Diabetes Awareness

New Brunswick, Canada

Blood Glucose Monitoring: Just the Basics

New Brunswick, Canada

Continuity of Care: From Diabetes Teaching to Your Counter

New Brunswick, Canada

Diabetes Awareness Night

New Brunswick, Canada

Update from the Canadian Diabetes Association Annual Meeting, Edmonton Alberta

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen and TwinJect Device

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen Device

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen Device

New Brunswick, Canada

Anaphylaxis and its Treatment with EpiPen Device

New Brunswick, Canada

Lantus Insulin & Welcome to Diabetes

New Brunswick, Canada

Achieving Diabetes Control with Optimal Blood Glucose Monitoring

Welcome to Diabetes

Best Practices Initiatives

New Brunswick, Canada

Sense of Urgency in Asthma Treatment

New Brunswick, Canada

Smoking Cessation

New Brunswick, Canada

Arthritis Overview and Treatments

New Brunswick, Canada

A Night of Women’s Health Issues

New Brunswick, Canada

OTC’s & Prescription Medications and Their Effect on Alertness

New Brunswick, Canada

Symptoms & Treatment of Anaphylaxis & EpiPen

New Brunswick, Canada

Pharmacist Bob’s Traveling Drug Show

Symptoms & Treatment of Anaphylaxis & EpiPen

New Brunswick, Canada

Symptoms & Treatment of Anaphylaxis & EpiPen

New Brunswick, Canada

Symptoms & Treatment of Anaphylaxis & EpiPen

Smoking Cessation

Smoking Cessation

Smoking Cessation

New Smoking Cessation Medications and Nicotine Replacement Therapies: Their Role in Smoking Cessation

Helping Your Patient Quit Smoking: The Pharmacist as Key Partner

Helping Your Patient Quit Smoking: The Pharmacist as Key Partner

Safe Use of EpiPens and Management of Allergic Reactions

Safe Use of EpiPens and Management of Allergic Reactions

Safe Use of EpiPens and Management of Allergic Reactions

Depression: A Community Perspective

Breast Cancer Treatments

Title

Title

Title

Title

Title

Title

Title

Title

Title